|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.38 | 89.41 | 104.18 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
364.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 1,067.21 | 1,268.38 | 577.12 | 301.26 | 353.49 | Adjustment | 296.41 | 231.79 | 307.88 | 246.33 | 133.53 | Changes In working Capital | -1,352.53 | -107.20 | 81.55 | 24.78 | -335.17 | Cash Flow after changes in Working Capital | 11.09 | 1,392.97 | 966.54 | 572.37 | 151.84 | Cash Flow from Operating Activities | -265.87 | 1,062.40 | 872.51 | 471.02 | 52.07 | Cash Flow from Investing Activities | -1,907.27 | -945.89 | -66.93 | -425.31 | -129.94 | Cash Flow from Financing Activities | 2,343.08 | -62.44 | -786.18 | -42.06 | 77.09 | Net Cash Inflow / Outflow | 169.94 | 54.07 | 19.40 | 3.65 | -0.78 | Opening Cash & Cash Equivalents | 116.08 | 62.01 | 42.61 | 38.97 | 37.39 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 0 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 0 | 0 | 0 | 0 | 0 | Closing Cash & Cash Equivalent | 286.02 | 116.08 | 62.01 | 42.62 | 36.62 |
|
|
|
|
|
|